GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 9
- Registration Number
- NCT00500461
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2018-03-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 453
- Registration Number
- NCT00499707
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: Pneumococcal conjugate vaccine GSK1024850A.Biological: Infanrix hexa.Biological: Meningococcal vaccine GSK134612.Drug: Paracetamol.
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 750
- Registration Number
- NCT00496015
- Locations
- 🇨🇿
GSK Investigational Site, Znojmo, Czechia
Bioequivalence and Food Effect Study in Healthy Volunteers
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- Drug: Formulation ADrug: Formulation BDrug: Formulation CDrug: Formulation EDrug: Formulation G
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT00495274
- Locations
- 🇮🇹
GSK Investigational Site, Verona, Veneto, Italy
Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 250
- Registration Number
- NCT00495469
- Locations
- 🇺🇦
GSK Investigational Site, Vinnitsa, Ukraine
15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.
- Conditions
- Sleep Initiation and Maintenance Disorders
- Interventions
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00495729
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
- Conditions
- Diabetes Mellitus, Type 2Obesity
- Interventions
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT00494767
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00495014
- Locations
- 🇺🇸
GSK Investigational Site, Evansville, Indiana, United States
Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients
- Conditions
- Lymphoma, Follicular
- Interventions
- Drug: Prednisolone, Prednisone or equivalent
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 59
- Registration Number
- NCT00494780
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693
- Conditions
- Cancer
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 70
- Registration Number
- NCT00493818
- Locations
- 🇺🇸
GSK Investigational Site, Durham, North Carolina, United States